Cassava Sciences Inc vs Nutanix Inc — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while Nutanix Inc trades at $64.37 (market cap $17.39B). The key difference: Nutanix Inc is far larger — about 364.2× Cassava Sciences Inc's market cap, and Nutanix Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | NTNX | |
|---|---|---|
Market Cap | $47.75M | $17.39B |
Sector | Health | Technology |
52-Week High | $4.64 | $81.12 |
52-Week Low | $0.87 | $34.41 |
Enterprise Value | -$34.93M | $16.90B |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9528, down 4.46% today, with a bearish technical outlook but strong analyst support (66.7% buy ratings). The company continues to post net losses and negative cash flows, though recent EPS beats show some operational improvement. Recent news highlights Q2 2026 results and business updates on Tuberous Sclerosis Complex therapies.
The outlook remains speculative due to persistent unprofitability and cash burn, but analyst optimism and a low P/B ratio of 0.75 may attract value investors. Key risks include execution challenges in drug development and reliance on financing amid negative earnings.
Nutanix (NTNX) trades at $64.32, down 0.22% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $0.47 surpassing the $0.36 expectation. Revenue grew to $2.54B in 2025 with a net income margin of 7.42%, while 2026 projections show improved profitability. Analyst sentiment remains positive with 20 buy ratings and a $57.80 consensus price target.
The outlook for NTNX is supported by strong earnings momentum and institutional interest, though high valuation multiples (P/E 67.71) and supply chain risks noted in recent news pose challenges. The stock's proximity to resistance at $65.00 suggests near-term consolidation may occur before further gains.
Trailing returns across standard periods
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →